文献速递甲状腺疾病

刺激后甲状腺球蛋白及球蛋白下降指数预测分化型甲状腺癌卓越反应

Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

该回顾性观察研究纳入1995至2010年治疗的1093例分化型甲状腺癌患者,评估消融前刺激后甲状腺球蛋白(presTg)、重组人TSH刺激后甲状腺球蛋白(sTg)及Tg下降指数(TRI)对长期卓越反应的预测能力。多因素分析显示淋巴结侵犯、presTg、sTg和TRI为独立预后因素;presTg<10 µg/L预测卓越反应阴性预测值达94%,sTg<1 µg/L及TRI>60%(局部晚期>62.5%)为敏感预测指标。

要点

  • presTg<10 µg/L对卓越反应阴性预测值94%,适用于T3/T4、N1期。
  • sTg<1 µg/L可预测卓越反应。
  • TRI>60%整体及>62.5%局部晚期为敏感预测指标。

核心结论

  • presTg、sTg和TRI是分化型甲状腺癌卓越反应及无病状态的高敏感预测指标。
  • 上述指标截断值也适用于较高肿瘤分期(T3/T4、N1)患者。

研究设计与样本

  • 观察性回顾性研究,纳入1995至2010年间治疗的1093例分化型甲状腺癌患者。
  • 患者均接受甲状腺切除术和放射性碘残余消融。
  • 消融前在甲状腺激素撤药状态下测量presTg,消融后6至12个月首次评估时测量重组人TSH刺激的sTg,并计算TRI。

主要发现

  • 多因素分析中,淋巴结侵犯(N1,OR=2.08;95%CI 1.19-3.64)、presTg(OR=4.04;95%CI 2.56-6.38)、sTg(OR=2.62;95%CI 2.05-3.34)和TRI(OR=0.43;95%CI 0.21-0.88)为影响初始治疗后疾病持续或复发的独立预后因素。
  • ROC分析确定presTg<10 µg/L预测卓越反应,阴性预测值为94%,并在较高分期(T3/T4、N1)中得到验证。
  • sTg<1 µg/L预测卓越反应。
  • TRI>60%(整个队列)和>62.5%(局部晚期疾病,T3/T4、N1)为卓越反应的敏感预测指标。

关键数值与推荐

  • presTg<10 µg/L预测卓越反应,阴性预测值94%。
  • sTg<1 µg/L预测卓越反应。
  • TRI>60%整体队列及>62.5%局部晚期(T3/T4、N1)为敏感预测指标。

临床怎么用

  • 可利用消融前presTg、消融后6-12个月sTg及计算的TRI来识别可能达到卓越反应的分化型甲状腺癌患者。
  • 对presTg<10 µg/L、sTg<1 µg/L或TRI>60%(局部晚期>62.5%)的患者,可考虑个体化调整主动监测 schedule。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Despite its good prognosis, differentiated thyroid cancer (DTC) is characterized by high rates of disease persistence and recurrence. Estimation of long-term remission (excellent response) thanks to specific parameters could help to individualize the active surveillance schedule. OBJECTIVE: Evaluation of the ability of stimulated thyroglobulin (Tg) and Tg reduction index (TRI) to predict long-term remission in patients with DTC managed by thyroidectomy and radioactive iodine (RAI) remnant ablation. PATIENTS AND INTERVENTIONS: Observational retrospective study of 1093 patients treated for DTC between 1995 and 2010. Preablation stimulated thyroglobulin (presTg) was measured under thyroid hormone withdrawal just before RAI. Recombinant human TSH-stimulated thyroglobulin (sTg) was measured at first evaluation of the initial management 6 to 12 months after RAI. TRI was calculated based on pre-Tg and sTg. RESULTS: After univariate and multivariate analyses, lymph node invasion (N1, OR = 2.08; 95% CI, 1.19 to 3.64), presTg (OR = 4.04; 95% CI, 2.56 to 6.38), sTg (OR = 2.62; 95% CI, 2.05 to 3.34), and TRI (OR = 0.43; 95% CI, 0.21 to 0.88) were identified as independent prognostic factors influencing the rate of disease persistence or recurrence after the initial management. Receiver operating characteristic analysis identified presTg cutoff (<10 µg/L) to predict excellent response, with a negative predictive value of 94%, and validated for higher stages (T3/T4, N1). Furthermore, sTg <1 µg/L predicts excellent response. TRI >60% for the entire cohort and 62.5% for locally advanced disease (T3/T4, N1) was sensitive predictor for excellent response. CONCLUSION: This study identifies presTg, sTg, and TRI as highly sensitive predictors of excellent response in patients with DTC and subsequently disease-free status. The cutoff of such parameters is also adapted for patients with higher tumor stages (T3/T4, N1).

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Barres B, Kelly A, Kwiatkowski F, et al. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers. J Clin Endocrinol Metab. 2019. PMID: 30785995. doi:10.1210/jc.2018-02680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。